DDInter1158 DDInter1951
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} (Compound) resembles {v} (Compound) Salsalate
Salsalate {u} (Compound) resembles {v} (Compound) Warfarin
Mesalazine {u} (Compound) resembles {v} (Compound) Droxidopa
Droxidopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Procarbazine
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} (Compound) resembles {v} (Compound) Salsalate
Salsalate {u} (Compound) resembles {v} (Compound) Warfarin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Mesalazine {u} (Compound) resembles {v} (Compound) Aminosalicylic acid
Aminosalicylic acid {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Mesalazine {u} (Compound) resembles {v} (Compound) Droxidopa
Droxidopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Warfarin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Mercaptopurine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a minor interaction that can limit clinical effects when taken with Warfarin
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may lead to a major life threatening interaction when taken with Warfarin
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine (Compound) resembles Salsalate (Compound) and Salsalate (Compound) resembles Warfarin (Compound)
Mesalazine (Compound) resembles Droxidopa (Compound) and Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal (Compound) resembles Salsalate (Compound) and Salsalate (Compound) resembles Warfarin (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Warfarin
Mesalazine (Compound) resembles Aminosalicylic acid (Compound) and Aminosalicylic acid (Compound) resembles Diflunisal (Compound) and Diflunisal may lead to a major life threatening interaction when taken with Warfarin
Mesalazine (Compound) resembles Droxidopa (Compound) and Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal (Compound) binds ALB (Gene) and ALB (Gene) is bound by Warfarin (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin